



ATTORNEYS AT LAW



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr. Lawrence B. Bugaisky Michael V. Messinger Judith U. Kirim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Albert L. Ferro\*
Donald R. Banowit
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Brian J. Del Buono
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhuller

Rae Lynn P. Guest George S. Bardmesser Daniel A. Klein Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller LuAnne M. DeSantis Ann E. Summerfield Aric W. Ledford Horlene C. Carlson Cynthia M. Bouchez Timothy A. Doyle\* Gaby L. Longsworth Lori A. Gordon Nicole D. Dretar Ted J. Ebersole Jyoti C. Iyer Laura A. Vogel Michael J. Mancuso Bryan S. Wade Aaron L. Schwartz Michael G. Penn\* Matthew E. Kelley\* Shannon A. Carroll\* Nicole R. Kramer\*

Registered Patent Agents • Karen R. Markowicz Nancy J. Leith Matthew J. Dowd Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Leffrey S. Lundgren Victoria S. Rutherford Michelle K. Holoubek Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse Christopher J. Walsh Lillana Di Nola-Baron Peter A. Socarras

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

\*Admitted only in Maryland \* Admitted only in Virginia • Practice Limited to Federal Agencies

March 2, 2005 AS FILED 3/4/05

INTERNET ADDRESS: JGOLD@SKGF.COM

Art Unit 1644

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Patent Application

Application No. 10/690,639; Filed: October 23, 2003

For: Pharmaceutical Composition of F(ab')<sub>2</sub> Antibody Fragments (As

Amended)

Inventors:

de Silanes et al.

Our Ref:

2099.0010001/JAG/LAV

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b) (3 pp.);
- 2. Form PTO-1449 listing 6 cited documents (2 pp);
- 3. One copy of 4 of the 6 cited documents (AM1, AN1, AT6, and AR7); and
- 4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents March 2, 2005 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jorge A. Goldstein Attorney for Applicants Registration No. 29,021

JAG/rjv Enclosures

368733\_1.DOC

MAR 0 4 2005 TO T

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

de Silanes et al.

Appl. No.: 10/690,639

Filed: October 23, 2003

For: Pharmaceutical Composition of

F(ab')<sub>2</sub> Antibody Fragments (As

Amended)

Confirmation No.: 9165

Art Unit: 1644

Examiner: Yunsoo, Kim

Atty. Docket: 2099.0010001/JAG/LAV

## First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Disclosure Statement is a continuation of the numbering on the Applicants' previous Information Disclosure Statement filed on August 20, 2004 in connection with the above-captioned application.

Copies of documents AM1 and AN1, AT6 and AR7 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), no copies of U.S. patents and patent application publications cited on the attached Form PTO-1449 are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits in accordance with 37 C.F.R. § 1.97(b)(3). No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jorge A. Goldstein Attorney for Applicants Registration No. 29,021

Date:

3/4/05

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

365375.1

			0	1				Page 1 of 2
			Man	٥	ATTY. DOCKET NO. 2099.0010001/JAG/LAV	10/6	PLICATION NO 90,639	
			PTO-1449   MAK	0 4 2005 -	FIRST NAMED INVENTOR Silanes <i>et al</i> .	₹		
FIRST SUPF	PLEMEN	TAL IN	EMENT DISC	しろしRはつ/ 17	FILING DATE October 23, 2003	AR1 164	UNIT 4	
			10	U.S. PATE	NT DOCUMENTS			
EXAMINER INITIAL		DO	CUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB	_						
	AC							
	AD							
	AE	_						
	AF2	6,4	48,054 B1	09/10/2002	Poznansky et al.			04/07/2000
	AG2	200	03/0049725 A1	03/13/2003	Heavner et al.			08/01/2001
	AH							
	Al				-			
	AJ							
	AK							
EXAMINER	- 1		F	OREIGN PA	TENT DOCUMENTS		T	Т
INITIAL		DO	CUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes
	AL							No
	AM1	wo	92/22324	12/23/1992	WIPO			Yes No
	AN1	wo	O 01/58469	08/16/2001	WIPO			Yes No
	AO							Yes No
	AP							Yes No
	т	1	OTHER (Includ	ling Author,	Title, Date, Pertinent I	Pages, etc.)		
	AR							
	AS							
	АТ	<u>6</u>	Calderon-Aranda, scorpion venum,"	E.S., et al., "N Toxicon 31:32	leutralizing capacity of mu 7-337, Pergamon Press L	rine sera induc td. (1993)	ed by different	antigens of
EXAMINER	1	1				DATE C	ONSIDERED	
					conformance with MPEP 609	. Draw line throu	gh citation if not	in conformance
and not consider	ed. Inclu	de copy	of this form with next	communication	to Applicant.			

		Page 2 of 2
	ATTY. DOCKET NO.	APPLICATION NO.
	2099.0010001/JAG/LAV	10/690,639
FORM PTO-1449	FIRST NAMED INVENTOR	
SUBSTITUTE SHENTAL INFORMATION DISCUSSION	Silanes et al.	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE	FILING DATE	ART UNIT
<u>STATEMENT</u>	October 23, 2003	1644

				U.S. PATE	NT DOCUMENTS			
EXAMINER INITIAL			DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	АН							
	Al							
	AJ							
	AK							
	J		F	OREIGN PA	TENT DOCUMENTS	<u>.</u>	L	
EXAMINER INITIAL			DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	
	AL							Yes No
	AM							Yes No
	AN							Yes No
	AO AP							Yes No
								Yes No
	OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							1
	AR	7	Licea, A.F., et al., FAB fragments of the monoclonal antibody BCF2 are capable of neutralizing the whole venom from the scorpion Centruroides noxius hoffman," Toxicon 34:843-847, Pergamon Press Ltd. (1996)					
	AS	7						
	AT						NOIDEDED	
EXAMINER						DATE CO	NSIDERED	

**EXAMINER**: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.